user-generated· product
Hantavirus vaccine enters Phase 3 trials by Q4 2026
Given the high fatality rate and WHO's focus on containment, pharmaceutical companies will accelerate vaccine development for hantavirus. A Phase 3 trial initiation by Q4 2026 would signal progress toward a potential market-ready solution.
product · Prediction Market
- Implied probability (Yes)
- 55%
More product markets
- Vercel’s Eve framework adoption exceeds 50% among enterprise AI deployments by Dec 2026 — 70% Yes
- OpenAI will delay its 2026 hardware launch due to Apple lawsuit — 55% Yes
- Netflix to introduce micro-episode format by December 2026 — 68% Yes
- Govee Glide Hexa Light Panels will see a 30% increase in sales by Q4 2026 — 70% Yes
- Coinbase launches new staking product by August 2026 — 55% Yes
- Competitor AI models adopt 'J-Space'-like reasoning by 2027-03-31 — 60% Yes
- Tesla partners with Sadi Thermal Machines for next-gen heat pump tech — 60% Yes
- Claude's J-Space adoption accelerates in enterprise AI tools — 70% Yes
Loading…